相关实验视频
Updated: May 17, 2025

10:31
Antigenic Liposomes for Generation of Disease-specific Antibodies
Published on: October 25, 2018
12.3K
[成年人的炎症性肌肉病变. [多价免疫球蛋白的位置]
Robert Rodriguez-Vigouroux1, Jörg D Seebach1, Geoffrey Urbanski1
1Service d'immunologie et d'allergologie, Hôpitaux universitaires de Genève, 1211 Genève 14.
Revue medicale suisse
|April 3, 2025
概括
高剂量静脉注射免疫球蛋白对治疗炎症性肌肉病,一组自身免疫性肌肉疾病的治疗有前途. 虽然它们是有效和安全的,但它们的高成本需要仔细考虑患者使用.
科学领域:
- 自身免疫性疾病是一种自身免疫性疾病.
- 类风湿病学 类风湿病学
- 神经学 神经学
背景情况:
- 炎症性肌肉病是一种复杂的自身免疫性疾病,影响骨肌肉.
- 这些多系统性疾病需要有效的治疗策略.
研究的目的:
- 审查静脉注射免疫球蛋白 (IVIG) 治疗的作用机制.
- 评估IVIG在治疗炎症性肌肉病的疗效.
- 在这种情况下,评估IVIG的安全性和局限性.
主要方法:
- 关于IVIG和炎症性肌肉病的现有研究的文献综述.
- 对高剂量IVIG的免疫调节性质的分析.
- 关于IVIG的有效性和安全性概况的综合证据.
主要成果:
- 静脉注射的免疫球蛋白具有显著的免疫调节能力.
- 有证据表明,IVIG可以在治疗炎症性肌肉病变方面有益.
- 在治疗自身免疫性疾病方面,IVIG显示出良好的安全性.
结论:
- 由于其免疫调节作用,IVIG是炎症性肌肉病的一个可行的治疗选择.
- 尽管有效,但IVIG的高成本和有限的可用性要求谨慎处方.
- 进一步的研究可能会优化IVIG在管理这些衰弱肌肉疾病的使用.
相关概念视频
Myasthenia Gravis: Overview and Treatment
1.0K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.0K
Myasthenia Gravis: Diagnostic Tests
568
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
568
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
103
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
103
Inflammatory Bowel Disease IV: Pharmacological Management
82
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
82
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
111
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
111
T Cell Types and Functions
703
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
703

